Evidence map›Paper›PMID 27066521›Full record

ArticleMovement disorders clinical practice2014

Clinical Response to IncobotulinumtoxinA, after Demonstrated Loss of Clinical Response to OnabotulinumtoxinA and RimabotulininumtoxinB in a Patient with Musician's Dystonia.

Vesper Fe Marie Llaneza Ramos, Barbara I Karp, Codrin Lungu, Katharine Alter, Mark Hallett

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Movement disorders clinical practice, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Neurotoxin Impurities: A Review of Threats to Efficacy.Plastic and reconstructive surgery. Global open · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Vesper Fe Marie Llaneza RamosHuman Motor Control Section, National Institutes of Health, Bethesda, Maryland, USA.
Barbara I KarpCNS, IRB, National Institutes of Health, Bethesda, Maryland, USA.
Codrin LunguNational Institutes of Health, Bethesda, Maryland, USA.
Katharine AlterFunctional and Applied Biomechanics Section, Rehabilitaion Medicine Department, National Institutes of Health, Bethesda, Maryland, USA; Mount Washington Pediatric Hospital, Washington, District of Columbia, USA.
Mark HallettHuman Motor Control Section, National Institutes of Health, Bethesda, Maryland, USA.

Funding

Pathophysiology of Involuntary Movements and Volitional DisordersZIANS002667 · NINDS · NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE · PI HALLETT, MARK · 2009 to 2023
$17.7M
PHYSIOLOGICAL ANALYSIS OF INVOLUNTARY MOVEMENTSZ01NS002667 · NINDS · NEUROLOGICAL DISORDERS AND STROKE · PI HALLETT, MARK A · 1985 to 2008
$2.2M
Intramural NIH HHS Z01 NS002667
6 · The paper itself

Abstract

Botulinum toxin is a mainstay therapy for dystonia. Formulations available are three types of botulinumtoxinA and one type of botulinumtoxinB.

Indexed as

incobotulinumtoxinAmusician’s dystoniaonabotulinumtoxinArimabotulinumtoxinB

Identifiers

PMID27066521
PMCPMC4822507

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.